Latest news for MedSmart Group (OTC:MSGP) Stock

MedSmart Group Inc is a men wellness center. It is a professional network of medical centers specializing in Anti-Aging Treatments that improve the overall health and quality-of-life of male patients in a comfortable, casual and discreet setting.

MEDSMART GROUP INC by MedSmart Group Inc.

MedSmart Group Inc

WIIM

MHUA

Meihua International Medical Technologies shares are trading higher after the company announced its NT-2000 surgical path analysis system successfully supported the worlds second 5G remote robot-assisted lobectomy.

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.abcellera.com&amp;esheet=54102052&amp;newsitemid=20240731236547&amp;lan=en-US&amp;anchor=AbCellera&amp;index=1&amp;md5=ca85afe5c365324c9fd840eadf4f664c">AbCellera</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABCL#NASDAQ">ABCL</a>) announced today that it has expanded its existing collaboration with Eli Lilly and Company (Lilly) to discover therapeutic antibodies for programs in immunology, cardiovascular disease, and neuroscience. The expansion builds upon the successful research collaboration <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Finvestors.abcellera.com%2Fnews%2Fnews-releases%2F2020%2FAbCellera-Announces-Multi-Year-Antibody-Discovery-Collaboration-with-Lilly%2Fdefault.aspx&amp;esheet=54102052&amp;newsitemid=20240731236547&amp;lan=en-US&amp;anchor=established&amp;index=2&amp;md5=41609539b505fb6add9b06be04c45378">established</a> in March 2020, which included eight de novo programs for targets selected by Lilly and an exclusive license to AbCellera's COVID-19 antibody program.
AbCellera has advanced all eight programs under the original agreement, and the licensed program resulted in emergency use authorization by the U.S. Food and Drug Administration for two COVID-19 antibody therapies co-developed by the companies.

Biotech

News

General

ABCL

AbCellera And Lilly Expand Collaboration To Develop Antibody Medicines

Keefe, Bruyette &amp; Woods analyst Timothy Switzer maintains LendingClub (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LC#NYSE">LC</a>) with a Market Perform and raises the price target from $10 to $11.5.

Price Target

Analyst Ratings

Keefe, Bruyette & Woods Maintains Market Perform on LendingClub, Raises Price Target to $11.5

Jefferies analyst Joseph Gallo maintains CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) with a Buy and lowers the price target from $400 to $300.

CRWD

Jefferies Maintains Buy on CrowdStrike Holdings, Lowers Price Target to $300

Edible Garden AG Incorporated ("Edible Garden" or the "Company") (NASDAQ:<a href="https://www.benzinga.com/stock/EDBL#NASDAQ">EDBL</a>, EDBLW))), a leader in controlled environment agriculture (CEA), locally grown, organic, and sustainable produce and products, today reported that its Vitamins and Supplements products achieved over 30% year-over-year sales growth for the second quarter.&nbsp; The Company expects this growth in Vitamins and Supplements products to have a favorable impact on profitability and cash flow from operations for the second quarter.

Guidance

EDBL

Edible Garden Reports Preliminary 30% YoY Sales Growth In Vitamins And Supplements For Q2 2024

RYTM

Rhythm Pharmaceuticals Announces European Commission Expansion Of IMCIVREE Marketing Authorization To Include Children Aged 2-5 With Obesity Due To Bardet Biedl Syndrome Or POMC, PCSK1, And LEPR Deficiency

Wall Street expects Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) to report $4.72 in earnings per share and $38.3 billion in revenues when the company releases second-quarter financials <a href="https://www.benzinga.com/calendars/earnings?tickers=META">after market hours on Wednesday</a>.
The stock is up 45.38% over the past year — 30.86% year-to-date.
Meta Platforms&#8217; current stock price of $463.22 reflects a strongly bearish trend, as it sits below its 5, 20, and 50-day exponential moving averages. This signals slight selling pressure in the market. See below.
<figure class="wp-block-image size-full"><a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent073124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="626" height="454" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/31072830/Screenshot-2024-07-31-at-4.55.17-PM.png" alt="" class="wp-image-467200" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/31072830/Screenshot-2024-07-31-at-4.55.17-PM.png 626w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/31072830/Screenshot-2024-07-31-at-4.55.17-PM-300x218.png 300w" sizes="(max-width: 626px) 100vw, 626px" /></a></figure>
<a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent073124&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
The eight-day simple moving average (SMA) is at $468.57; the 20-day and 50-day SMAs are $490.23 and $491.29, respectively. 
All three indicators suggest bearish momentum around Meta stock.
<h2 class="wp-block-heading">2 Indicators Hint At Possible Reversal In Meta Stock Trend</h2>
Furthermore, the 200-day SMA is positioned at $431.72, indicating a bullish signal over the long term, given the current price is above this level.
<figure class="wp-block-image size-full"><a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent073124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="626" height="454" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/31072839/Screenshot-2024-07-31-at-4.54.36-PM.png" alt="" class="wp-image-467201" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/31072839/Screenshot-2024-07-31-at-4.54.36-PM.png 626w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/31072839/Screenshot-2024-07-31-at-4.54.36-PM-300x218.png 300w" sizes="(max-width: 626px) 100vw, 626px" /></a></figure>
<a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent073124&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
The Moving Average Convergence Divergence (MACD) indicator reads -10.57, reinforcing the bearish sentiment. 
Meta&#8217;s Relative Strength Index (RSI) is 39.79, which indicates that the stock is approaching oversold territory, suggesting that selling momentum may soon weaken.
The Bollinger Bands (25) range from $443.04 to $545.41, and with the stock price trading in the lower band, this supports a bearish perspective, indicating potential downward momentum. 
Overall, Meta stock's technical indicators are aligned towards a bearish outlook, though the RSI and 200-day SMA hint at a possible opportunity for reversal if buying pressure increases.
Read Also: <a href="https://www.benzinga.com/markets/equities/24/07/40047183/meta-hit-with-largest-ever-state-privacy-fine-texas-ag-secures-1-4b-settlement">Meta Hit with Largest-Ever State Privacy Fine – Texas AG Secures $1.4B Settlement</a>
<h2 class="wp-block-heading">Meta Analysts See 20% Upside</h2>
Meta Ratings &amp; Consensus Estimates:<a href="https://www.benzinga.com/quote/META/analyst-ratings"> The consensus analyst rating</a> on Meta stock stands at a Buy currently with a price target of $532.43. Recent analyst ratings from JMP Securities, Wedbush, and Bernstein suggest a 20.10% upside for Meta stock with an average price target of $556.67.
META Price Action: Meta stock closed the trading day of Tuesday at $463.19, down 0.54%.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/07/40059087/nasdaq-tumbles-amid-decline-in-tech-stocks-greed-index-moves-to-fear-zone">Nasdaq Tumbles As Microsoft, Nvidia And Other Tech Stocks Decline: Greed Index Moves To &#8216;Fear&#8217; Zone</a></li>
</ul>

Analyst Color

Earnings

Technicals

Tech

Trading Ideas

Meta Faces Slight Selling Pressure Ahead Of Q2 Earnings: Bearish Charts Suggest 20% Upside Potential

A Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) vehicle, operating on the company&#8217;s &#8220;Full Self Driving&#8221; system, was implicated in a fatal accident near Seattle in April, leading to the death of a motorcyclist.
What Happened: The fatal accident was discovered by investigators from the Washington State Patrol after examining the event-data recorder on the 2022 Tesla Model S, as stated by agency spokesman Capt. Deion Glover. The investigation is still ongoing, with the Snohomish County Prosecutor to decide on any potential charges, AP News <a href="https://apnews.com/article/tesla-full-self-driving-motorcyclist-killed-d3393396521c373fe5df5a44d2d9637f?utm_campaign=TrueAnthem&amp;utm_medium=AP&amp;utm_source=Twitter">reported</a> on Wednesday.
The driver, a 56-year-old man, confessed to using Tesla&#8217;s Autopilot system and being distracted by his cellphone while the car was in motion. He was subsequently arrested for investigation of vehicular homicide. The victim, Jeffrey Nissen, 28, of Stanwood, Washington, was declared dead at the scene. This incident marks the second death in the U.S. involving Tesla&#8217;s &#8220;Full Self-Driving&#8221; system.
Tesla has yet to respond to Benzinga&#8217;s queries.
See Also: <a href="https://www.benzinga.com/news/24/07/40034205/transportation-secretary-pete-buttigieg-says-china-understands-strategic-value-of-dominating-market?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Transportation Secretary Pete Buttigieg Says China Understands &#8216;Strategic Value&#8217; Of Dominating Market, Terms Ideological Differences On EVs &#8216;Frustrating:&#8217; &#8216;There Should Be Nothing Ideological About That…&#8217;</a>
Why It Matters: Tesla CEO Elon Musk recently made a statement that the &#8220;Full Self Driving&#8221; system should be capable of operating without human supervision by the end of this year. However, Tesla maintains that neither its &#8220;Full Self-Driving&#8221; nor its Autopilot system can drive itself and that human drivers must be prepared to take control at any time.
This incident comes in the wake of a report questioning Tesla&#8217;s <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/40023293/tesla-fsd-stunningly-good-but-not-useful-today-analyst-questions-self-driving-effor">autonomous driving capabilities</a> after a near-crash experience. Despite the concerns, Musk remains confident that government approval will not hinder the deployment of robotaxis, stating that if billions of miles of data show that unsupervised FSD is safer than humans, no regulator could stand in the way.
Earlier this year, Tesla released a <a href="https://www.benzinga.com/news/24/05/38979185/tesla-breaks-silence-on-vehicle-safety-data-after-a-year-autopilot-boasts-lower-accident-risk-vs-man">vehicle safety data report</a>, indicating a significantly lower crash rate for vehicles using Autopilot compared to those driven manually. However, the recent fatal accident raises questions about the safety of Tesla&#8217;s self-driving technology.
Price Action: Tesla was trading 1.02% higher at $224.90 at the time of writing during Wednesday&#8217;s pre-market, according to <a href="https://pro.benzinga.com">Benzinga Pro</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/07/40028740/tesla-ceo-elon-musk-turns-down-possibility-of-model-s-plaid-plus-variant-upcoming-roadster-set-to-fi?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Tesla CEO Elon Musk Turns Down Possibility Of Model S Plaid Plus Variant, Upcoming Roadster Set To Fill That Gap Instead</a></li>
</ul>
Image via Shutterstock
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noreferrer noopener">Pooja Rajkumari</a>

TSLA

Tesla's FSD System Under Scrutiny After Fatal Motorcycle Accident Near Seattle

GigaMedia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GIGM#NASDAQ">GIGM</a>) reported quarterly losses of $(0.06) per share. This is a 20 percent decrease over losses of $(0.05) per share from the same period last year. The company reported $721.00 thousand in sales this quarter. This is a 29.66 percent decrease over sales of $1.02 million the same period last year.

GIGM

GigaMedia Q2 EPS $(0.06) Down From $(0.05) YoY, Sales $721.00K Down From $1.02M YoY

Keefe, Bruyette &amp; Woods analyst Aidan Hall reiterates Houlihan Lokey (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLI#NYSE">HLI</a>) with a Market Perform and raises the price target from $139 to $154.

Reiteration

Keefe, Bruyette & Woods Reiterates Market Perform on Houlihan Lokey, Raises Price Target to $154

Thousands of Customers Depend on The Combined Power of Box and Slack to Securely Collaborate With Their Content
Box, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOX#NYSE">BOX</a>), the leading Intelligent Content Cloud, and AI-powered work operating system, Slack, a Salesforce company, (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) today announced an expanded partnership that brings secure AI to enterprise content to transform the way organizations work. Available today, joint customers can now access <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.boxinvestorrelations.com%2Fnews-and-media%2Fnews%2Fpress-release-details%2F2024%2FBox-Announces-Powerful-Enhancements-to-Box-AI-for-Intelligent-Content-Management%2Fdefault.aspx&amp;esheet=54102197&amp;newsitemid=20240731610629&amp;lan=en-US&amp;anchor=unlimited&amp;index=1&amp;md5=f8f502c5615d7358984d20a35c1fef9b">unlimited</a> Box AI queries directly in Slack, allowing users to ask critical questions and uncover timely insights from Box files in the same place they're already working. The companies also announced several joint enhancements to the integration, including dynamic and secure file previews of Box files in Slack, improved workflow automation across the two platforms, and more.

Box And Slack, A Salesforce Company, Expand Partnership With The Launch Of Box AI In Slack

Jefferies analyst David Kelley maintains CCC Intelligent Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCCS#NASDAQ">CCCS</a>) with a Buy and lowers the price target from $14 to $13.

CCCS

Jefferies Maintains Buy on CCC Intelligent Solutions, Lowers Price Target to $13

PARA

PARAA

Apex Capital Trust Submits Competing $43B All-Cash Offer For Paramount Global; Proposes To Purchase 100% Of NAI's Capital Stock And Assumes $15.8B In Debt; Offer Sent To National Amusements And Investment Firm To Facilitate "Go-Shop" Provision Against Skydance Deal

On CNBC's &#8220;Mad Money Lightning Round,&#8221; Jim Cramer said he likes Blackstone Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>). &#8220;They have a lot of great companies in house that are going to do <a href="https://www.benzinga.com/news/earnings/24/07/39839457/blackstone-q2-earnings-miss-stock-dips-as-costs-rise">very well,&#8221; he added</a>.
On July 18, Blackstone reported second-quarter fiscal year 2024 adjusted revenues of $2.796 billion, beating the consensus of $2.619 billion.
When asked about Borr Drilling Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BORR#NYSE">BORR</a>), Cramer said he always goes with the best, which is Schlumberger NV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>).
On May 23, Borr Drilling reported better-than-expected first-quarter sales results and raised its dividend.
Lowe&#8217;s Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOW#NYSE">LOW</a>) is the kind of stock that should be bought right here, right now ahead of the Federal Reserve's rate cut cycle. &#8220;I would pick some up tomorrow,&#8221; he added.
On May 31, the company declared a quarterly cash dividend of $1.15 per share, payable Aug. 7 to shareholders of record as of July 24.
&#8220;I was mystified and surprised at that conference call, which was absolutely terrible, Cramer said about DexCom, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>). &#8220;I think Abbott (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) is a better play.&#8221;
On July 25, DexCom reported worse-than-expected second-quarter revenue results and issued weak revenue guidance.
When asked about Marvell Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>), he said, &#8220;They're two different things. Marvell the stock is probably being hurt, but Marvell the company, Matt Murphy [Chairman and CEO at Marvell] is doing a terrific job. I actually would own the stock.&#8221;
On July 30, the company introduced its Structera line of Compute Express Link (CXL) devices, designed to address memory performance and scaling challenges in general-purpose servers for cloud data centers.
The &#8220;Mad Money&#8221; host recommended selling Joby Aviation, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JOBY#NYSE">JOBY</a>).
Joby Aviation will release its second quarter financial results after the closing bell on Wednesday, Aug. 7.
When asked about Edwards Lifesciences Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>), he said, &#8220;You want to swap over to Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>).&#8221;
On July 24, Edwards Lifesciences reported worse-than-expected second-quarter sales results and issued third-quarter guidance below estimates. Also, the company acquired JenaValve and Endotronix.
Price Action:
<ul>
<li>Borr Drilling shares rose 2.3% to settle at $6.60 on Tuesday.</li>
<li>Marvell shares fell 2.6% to close at $62.80 on Tuesday.</li>
<li>Joby Aviation shares fell 1.9% to close at $6.09.</li>
<li>Blackstone shares rose 0.3% to settle at $141.34.</li>
<li>Dexcom rose 3.3% to close at $69.70 during Tuesday's session.</li>
<li>Edwards Lifesciences shares fell 0.2% to settle at $63.64 on Tuesday.</li>
<li>Lowe&#8217;s gained 0.7% to close at $241.40 on Tuesday.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/07/40059087/nasdaq-tumbles-amid-decline-in-tech-stocks-greed-index-moves-to-fear-zone">Nasdaq Tumbles As Microsoft, Nvidia And Other Tech Stocks Decline: Greed Index Moves To &#8216;Fear&#8217; Zone</a></li>
</ul>
Photo: Shutterstock

Long Ideas

Markets

BORR

DXCM

JOBY

MRVL

Jim Cramer Says This Home Improvement Chain Is A Buy Ahead Of Fed Rate Cut Cycle: 'I Would Pick Some Up Tomorrow'

<ul>
<li>Alcyone's ThecaFlex is an implantable medical device under investigation for routine subcutaneous administration of therapeutics to the cerebrospinal fluid (CSF).</li>
<li>The first stage of the pivotal IDE PIERRE trial has been completed.</li>
<li>10 spinal muscular atrophy (SMA) patients have undergone ThecaFlex implantation and have received nusinersen through the device.</li>
<li>No device-related adverse events, including infections, were observed in the 30 days after implantation.</li>
<li>FDA has agreed to an additional 80-SMA patient, 30-center, enrollment after review of the clinical data by Data Monitoring Safety Committee of first 10 SMA patients implanted.</li>
</ul>
LOWELL, Mass., July 31, 2024 /PRNewswire/ --&nbsp;Alcyone Therapeutics Inc. (Alcyone), a clinical-stage biotechnology company pioneering next-generation precision genetic therapies and precision delivery solutions of therapies for complex neurological conditions, announced today that the U.S. Food and Drug Administration (FDA) has provided approval to continue enrollment of the <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4223192-1&amp;h=352701505&amp;u=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT05866419&amp;a=PIERRE+study">PIERRE study</a>&nbsp;(<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4223192-1&amp;h=1771403035&amp;u=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT05866419&amp;a=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT05866419">https://clinicaltrials.gov/ct2/show/NCT05866419</a>) to evaluate the safety and effectiveness of the ThecaFlex DRx&#x2122;&nbsp;subcutaneous port and intrathecal catheter system for chronic intrathecal access, CSF aspiration, and delivery of SPINRAZA&#xAE; (nusinersen) in SMA patients as an alternative to repeat lumbar puncture (LP).

BIIB

IONS

Alcyone Therapeutics Announces Continued Enrollment Approval From FDA Of The PIERRE Pivotal IDE Clinical Study Of The ThecaFlex DRx System For Administration Of Nusinersen

Keefe, Bruyette &amp; Woods analyst Ryan Krueger reiterates Globe Life (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GL#NYSE">GL</a>) with a Outperform and raises the price target from $110 to $118.

Keefe, Bruyette & Woods Reiterates Outperform on Globe Life, Raises Price Target to $118

Company engages Prospect Hotel Advisors for their specialized expertise
LAS VEGAS, July 31, 2024 /PRNewswire/ --&nbsp;Allegiant Travel Company ((<a href="https://c212.net/c/link/?t=0&amp;,%20l=en&amp;,%20o=4223126-1&amp;,%20h=2370561295&amp;,%20u=http%3A%2F%2Fir.allegiantair.com%2F&amp;,%20NASDAQ:%3Ca%20class=">ALGT</a>) announced today it has retained global hospitality asset management firm Prospect Hotel Advisors, LLC to conduct a strategic review of its hotel, Sunseeker Resort Charlotte Harbor.
The recently opened resort, located in Southwest Florida, is a wholly owned subsidiary of Allegiant Travel Company and is Florida's premier gulf coast oasis, offering magnificent views, amazing pools, world class restaurants, championship golf, a full-service spa and many other amenities.
Prospect Hotel Advisors will advise the company on strategies that maximize the value of Sunseeker Resort. The engagement aims to improve financial performance and help accelerate the strategic positioning of the hotel in conjunction with the existing experienced management team.

ALGT

Allegiant To Conduct A Strategic Review Of Its Hotel, Sunseeker Resort Charlotte Harbor

<a href="https://www.theinformation.com/articles/tiktok-spending-drove-microsofts-booming-ai-business" title="https://www.theinformation.com/articles/tiktok-spending-drove-microsofts-booming-ai-business">https://www.theinformation.com/articles/tiktok-spending-drove-microsofts-booming-ai-business</a>

MSFT

'TikTok Spending Drove Microsoft's Booming AI Business' - The Information

FULC

Fulcum Therapeutics shares are trading higher after the company reported a year-over-year increase in Q2 EPS results.

Haggen Food &amp; Pharmacy now available for same-day delivery from Instacart
SAN FRANCISCO and BOISE, Idaho, July 31, 2024 /PRNewswire/ -- Instacart (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CART#NASDAQ">CART</a>), the leading grocery technology company in North America, and Albertsons Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACI#NYSE">ACI</a>) today announce the launch of Instacart pickup services and Albertsons Rapid convenience delivery nationwide at banners&#x2A; including Safeway, Albertsons, Shaw's, ACME, Jewel-Osco, Randalls and Vons. Additionally, Haggen Food &amp; Pharmacy is now available on the Instacart App for same-day delivery. This program expansion provides Instacart customers with greater access to groceries and household essentials alongside the quality and fresh assortment they expect from Albertsons Cos. banner stores.

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

Comments

MedSmart Group

News

Latest news for MedSmart Group (OTC:MSGP) Stock